LOGIN  |  REGISTER
Recursion
Viking Therapeutics

Neogen® to Participate in the 44th Annual William Blair Growth Stock Conference

May 30, 2024 | Last Trade: US$14.90 0.19 -1.26

LANSING, Mich., May 30, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today that the Company will participate in the 44th Annual William Blair Growth Stock Conference in Chicago, Illinois, on Tuesday, June 4, 2024.

John Adent, Neogen's President and Chief Executive Officer, will present at 8:00 a.m. Central Time.

Presentation materials will be posted to the Neogen Investor Relations website on the morning of June 4. To access them, along with the event webcast link, please visit the Events & Presentations section at neogen.com/investor-relations/events-presentations.

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

Contact

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Chimerix

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB